The trial revealed a linear correlation between higher tumor burden and anti-PD1 and anti-programmed death ligand (PD-L1) checkpoint inhibitors, explained as the immune system responding to reactivation.

Multiple clinical trials are currently underway examining the possible synergistic effects of combining chemotherapy with immunotherapies for patients with bladder cancer and other...